A model of human tumor dormancy: An angiogenic switch from the nonangiogenic phenotype

Journal of the National Cancer Institute

Volumn 98, Issue 5, 2006, Pages 316-325

  Naumov, George N ^a   Bender, Elise ^a   Zurakowski, David ^a   Kang, Soo Young ^a   Sampson, David ^a   Flynn, Evelyn ^a   Watnick, Randolph S ^a   Straume, Oddbjorn ^b   Akslen, Lars A ^a,b   Folkman, Judah ^a,c   Almog, Nava ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF BERGEN   (Norway)

^c Karp Family Research Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYCLINE; KI 67 ANTIGEN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; THROMBOSPONDIN 1; VASCULOTROPIN 165;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VESSEL FUNCTION; BREAST ADENOCARCINOMA; CANCER GROWTH; CARCINOGENESIS; CELL ISOLATION; CELL PROLIFERATION; COMPARATIVE STUDY; CONCEPTUAL FRAMEWORK; CONTROLLED STUDY; DORMANCY; GENE SWITCHING; GLIOBLASTOMA; GROWTH CURVE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; OSTEOSARCOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCIBILITY; SCID MOUSE; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA; PHENOTYPE; THROMBOSPONDIN 1; TIME FACTORS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33644763050     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj068     Document Type: Article

References (34)

1. Folkman J, Cole P, Zimmerman S. Tumor behavior in isolated perfused organs: In vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 1966;164:491 .
2. Folkman J, Kalluri R. Cancer without disease. Nature 2004;427:787 .
3. Gimbrone MA Jr, Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972;136:261-76.
4. Folkman J. Antiangiogenesis agents. In Cancer: Principles and Practice of Oncology, 7th ed. VT DeVita Jr, S Hellman, and SA Rosenberg, editors. Philadelphia (PA) Lippincott Williams & Wilkins; 2004. pp. 2865-82.
5. Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. Breast cancer and atypia among young and middle-aged women: A study of 110 medicolegal autopsies. Br J Cancer 1987;56:814-9.
6. Black WC, Welch HG. Advances in diagnostic imaging and overestimators of disease prevalence and the benefits of therapy. N Engl J Med 1993;328:1237-43.
7. Feldman AR, Kessler L, Myers MH, Naughton MD. The prevalence of cancer. Estimates based on the Connecticut Tumor Registry. N Engl J Med 1986;315:1394-7.
8. Demicheli R, Terenziani M, Valagussa P, Moliterni A, Zambetti M, Bonadonna G. Local recurrences following mastectomy: Support for the concept of tumor dormancy. J Natl Cancer Inst 1994;86:45-8.
9. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004;10:8152-62.
10. Mizuno I, Izeki O, Nakahara S, Kawamoto K, Onga T, Matsuoka H, et al. Disseminated carcinomatosis of the bone marrow occurring 11 years after subtotal gastrectomy for gastric cancer. Rinsho Ketsueki 1998;39:670-5.
11. Crowley NJ, Seigler HF. Relationship between disease-free interval and survival in patients with recurrent melanoma. Arch Surg 1992;127:1303-8.
12. Badgley CE, Batts M. Osteogenic sarcoma: An analysis of eighty cases. Arch Surg 1941;43:541-50.
13. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-53.
14. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
15. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
16. Hanahan D, Christofori G, Naik P, Arbeit J. Transgenic mouse models of tumor angiogenesis: The angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 1996;14:2386-93.
17. Achilles EG, Fernandez A, Allred EN, Kisher O, Udagawa T, Beecken WD, et al. Heterogeneity of angiogenic activity in a human liposarcoma: A proposed mechanism for "no take" of human tumors in mice. J Natl Cancer Inst 2001;93:1075-81.
18. Udagawa T, Fernandez A, Achilles E, Folkman J, D'Amato RJ. Persistence of microscopic human cancers in mice: Alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J 2002;16:1361-70.
19. Watnick RS, Cheng Y, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003;3:219-31.
20. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
21. Miles A, Miles E. Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea pigs. J Physiol 1952;118:228-57.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
23. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
24. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-92.
25. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
26. Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, Kahn CR, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002;295:140-3.
27. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, et al. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science 1999;285:245-8.
28. Good DJ, Polverini PJ, Rastinejad F, Le-Beau MM, Lemons RS, Frazier WA, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 1990;87:6624-8.
29. Rastinejad F, Polverini PJ, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989;56: 345-55.
30. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994;54:6504-11.
31. Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999;5: 1041-56.
32. Aguirre-Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999;147:89-104.
33. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. Urokinase receptor and fi bronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 2001;12:863-79.
34. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003;63:1684-95.